Aisha Latif
@AshAtWorkWork
Followers
18
Following
16
Media
426
Statuses
942
Want reliable scaling results on the first try? See for yourself how our WAVE bioreactor on our bioreactor scaler tool can help you save time and resources! https://t.co/2otFdGtJ5I
cytiva.link
Bioreactor Scaler is a software platform that predicts scaling in silico to help you define key process parameters, enabling seamless tech transfer.
0
0
0
Be an imaging pro! Receive 15% off on imaging instruments, including the ImageQuant 800 and Typhoon systems. You'll also receive a complimentary ImageQuant 800 Lego model! https://t.co/PWiPT0DkE3
#imagingtechnology
#lifesciences
#biopharma
cytiva.link
Landing page for imaging pro promotion for academic customers
0
0
0
Discover the Imaging Pro advantage from Cytiva! Get up to 15% off on Typhoon and ImageQuant 800 instruments when you request a quote - plus we'll throw in a free ImageQuant 800 Lego model. https://t.co/JmrYl34VGc
cytiva.link
Landing page for imaging pro promotion for academic customers
0
0
1
Get your team up to speed on cell therapy development and manufacturing. Register for our free online cell therapy introductory course — eCELLT1 — where you'll learn GMP techniques and how to optimize your processes. https://t.co/wUNcjs3lJA
#celltherapydevelopment
0
0
0
Ever wondered how manufacturers went from producing zero mRNA vaccines per year to producing millions? Katarina Stenklo pulls back the curtain on the rapid scale-up of nucleic acid therapeutics. https://t.co/Wria3X8awT
#nucleicacidtherapeutics
#mRNA
#oligos
0
0
0
With its broad range of applications, from early process development to late-stage scale-up, troubleshooting, and CMC, it’s the ultimate tool for optimizing your chromatography processes. Learn more: https://t.co/8YLaT0WQAV
#insilico #chromatography #ChromatographyModeling
cytiva.link
0
0
0
We interviewed our colleague George White to learn about his role in moving our business towards #celltherapy development when the viability of such therapies was far from certain. Here's what he had to say: https://t.co/t4ZJ2KeTCN
#cellandgenetherapy
#CART
cytiva.link
0
0
0
Who's up for a bit of summer reading? Take our quiz to test your grasp of antibody variants, antibody domains, and considerations for setting up purification protocols. Then, download our eBook to enhance your knowledge. https://t.co/LkTctFh8LG
#mAbs
#antibodies
#biologics
0
0
0
Liquid biopsy is the topic of this episode. How can these biopsies find biomarkers for disease in a less invasive manner? Let’s find out. https://t.co/tHTvSXWnQ9
#liquidbiopsy
#DiscoveryMatters
#biomarkers
cytiva.link
In this episode, we dive into the potential of liquid biopsies as a method to detect deadly diseases. We speak with three experts – Marta Herreros, Rik ..
0
0
0
Watch our on-demand webinar featuring Alex de Winter and Sabrina Carmichael who share insights and answer questions on manufacturing and funding challenges #translationalresearchers need to consider. https://t.co/xyXHLaph5v
#translationalmedicine
#biomanufacturing
cytiva.link
You’ve read all the articles, absorbed all the advice — is your research ready to launch off the starting block?In the Hurdles and High Jumps series, ..
0
0
0
Our resolution for 2023 and beyond is to help you get your team up to speed on #celltherapy. Register your staff today for our free Online Advanced eCELLT1 course. https://t.co/7f35iPecpN
#professionaldevelopment
cytiva.link
Register now for our interactive online course.
0
0
0
This fixed-bed bioreactor system will help you to gain productivity without increasing the footprint of your industrialization of animal cell culture processes. https://t.co/BEJCmiip9v
#bioreactor
#lifesciences
#bioprocessing
cytiva.link
0
0
0
Cytiva translational medicine advisor, Preston Keller, explores the impact of regulatory considerations, GMP manufacturing, and more on translational research and the development of novel therapeutics. Use the link to get in touch with Preston: https://t.co/3nuPfpntm8
0
2
2
Cytiva's innovative Protein Select technology is designed to streamline and accelerate recombinant protein purification.
genengnews.com
The diverse set of recombinant protein--of which there are 1,800 in the global pipeline this year alone--often lacks affinity binding partners to facilitate purification.
0
1
1
Asia-Pacific has emerged as the second largest region for ATMP trials, surpassing Europe as governments across Singapore, South Korea, Australia actively back up the mRNA innovation.
0
0
0
Cytiva's innovative Protein Select technology is designed to streamline and accelerate recombinant protein purification.
genengnews.com
The diverse set of recombinant protein--of which there are 1,800 in the global pipeline this year alone--often lacks affinity binding partners to facilitate purification.
0
1
1
As antibiotics lose efficacy, phage viruses could be the answer. Read the article to learn more: https://t.co/LGAORygiCV
#antibioticresistance
#biopharma
cytiva.link
As antibiotics lose efficacy, phage viruses could be the answer.
0
0
0
Cytiva's Andrew Schulman discusses why the biotechnology industry must continue working to advance allogeneic cell therapies. #celltherapies #genomicmedicine #cytiva
technologynetworks.com
Andrew Schulman explores why we need allogeneic therapies, the importance of collaboration to keep the momentum, and challenges and predictions for the future.
0
1
1
With smaller batches and more personalized medicines on the rise, the industry's ability to produce advanced therapies at scale gets more challenging. Our flexible approach to aseptic filling in biomanufacturing aims to change that. https://t.co/5Y2Eke4U21
#precisionmedicine
cytiva.link
Smaller batch, personalized medicines show great promise. They're just not very scalable. Cytiva’s flexible approach to aseptic filling in biomanufa..
0
0
1
Antisense technology is allowing the n-Lorem foundation to develop treatments for ultra-rare patients with genetic mutations. Connor is one of those patients awaiting his therapy. https://t.co/VaRN9fauXr
#rarediseases
#genetics
cytiva.link
The n-Lorem foundation is using antisense technology to build a better future for those with ultra-rare genetic mutations, one patient at a time.
0
0
0